Abdul Hafeez, MD
Psychiatry · Redford, MINPI 1770593766
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 65.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $6,976 and has fallen 93.2% since, to $472 in 2025. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $43.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$9K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$687
- AbbVie$392
- E.r. Squibb & Sons, L.L.C.$389
- Indivior Inc.$379
- plus $2K from 10 others
What the payments were for
- Speaking & faculty fees$7,06854%
- Travel & lodging$4423%
- Food & beverage$5,30941%
- Education$2352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 48 | $8,507 |
| Neurocrine Biosciences, Inc. | 70 | $1,159 |
| Alkermes, Inc. | 35 | $687 |
| AbbVie(2 entities) | 37 | $392 |
| E.r. Squibb & Sons, L.L.C. | 15 | $389 |
| Indivior Inc. | 17 | $379 |
| Otsuka America Pharmaceutical, Inc. | 19 | $347 |
| Sunovion Pharmaceuticals Inc. | 16 | $273 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $249 |
| Lundbeck LLC | 12 | $222 |
| Johnson & Johnson | 7 | $139 |
| Axsome Therapeutics, Inc. | 3 | $88 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $72 |
| Acera Surgical, Inc. | 1 | $46 |
| Validus Pharmaceuticals LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$8,047
- ARISTADA$500
- ARISTADA INITIO$125
- SUBLOCADE$121
How this compares
$13,053 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 144 | $443,172 |
| UzedyRisperidone | 40 | $193,581 |
| VraylarCariprazine Hcl | 97 | $137,803 |
| RexultiBrexpiprazole | 94 | $134,011 |
| Risperdal ConstaRisperidone Microspheres | 65 | $112,481 |
| TrintellixVortioxetine Hydrobromide | 223 | $107,201 |
| IngrezzaValbenazine Tosylate | 11 | $89,943 |
| Abilify MaintenaAripiprazole | 27 | $78,293 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $41,389 |
| Lurasidone Hcl | 82 | $32,635 |
| Aripiprazole | 250 | $24,411 |
| Paliperidone ErPaliperidone | 81 | $23,252 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 15 | $20,093 |
| CaplytaLumateperone Tosylate | 12 | $19,987 |
| Fluphenazine Hcl | 110 | $19,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $139 | $555,653209 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $347 | $212,305121 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy, Loxapine | $8,507 | $195,60285 claims |
| AbbVieVraylar | $392 | $137,80397 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $72 | $107,201223 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,159 | $89,94311 claims |
| Alkermes, Inc.Lybalvi | $687 | $41,38924 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $249 | $19,98712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Redford
- Mohamed SiddiqueRedford$10K
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
- Samuel WedesLivonia$158K
- Arash JavanbakhtDetroit$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.